Treatment response of all randomized patients
| . | 140 mg once daily (n = 158) . | 70 mg twice daily (n = 159) . | ||
|---|---|---|---|---|
| n/N . | % . | n/N . | % . | |
| Hematologic response | ||||
| Overall (95% CI) | 119/158 | 75 (67.8-81.8) | 120/159 | 76 (68.0-81.9) |
| Imatinib-resistant | 83/117 | 71 | 86/116 | 74 |
| Imatinib-intolerant | 36/41 | 88 | 34/43 | 79 |
| MHR | ||||
| Overall (95% CI) | 105/158 | 66 (58.5-73.8) | 108/159 | 68 (60.1-75.1) |
| Without MHR at baseline | 78/129 | 60 | 73/118 | 62 |
| Imatinib-resistant | 74/117 | 63 | 79/116 | 68 |
| Imatinib-intolerant | 31/41 | 76 | 29/43 | 67 |
| CHR | ||||
| Overall (95% CI) | 75/158 | 47 (39.5-55.6) | 82/159 | 52 (43.5-59.6) |
| Without CHR at baseline | 63/142 | 44 | 59/128 | 46 |
| Imatinib-resistant | 59/117 | 50 | 59/116 | 51 |
| Imatinib-intolerant | 16/41 | 39 | 23/43 | 53 |
| NEL | ||||
| Overall (95% CI) | 30/158 | 19 (13.2-26.0) | 26/159 | 16 (11.0-23.0) |
| Imatinib-resistant | 15/117 | 13 | 20/116 | 17 |
| Imatinib-intolerant | 15/41 | 37 | 6/43 | 14 |
| MCyR | ||||
| Overall (95% CI) | 61/158 | 39 (31.0-46.7) | 68/159 | 43 (35.0-50.8) |
| Without MCyR at baseline | 48/143 | 34 | 57/147 | 39 |
| Excluding Ph− patients | 59/155 | 38 | 68/159 | 43 |
| Imatinib-resistant | 42/117 | 36 | 49/116 | 42 |
| Imatinib-intolerant | 19/41 | 46 | 19/43 | 44 |
| CCyR | ||||
| Overall (95% CI) | 51/158 | 32 (25.1-40.2) | 52/159 | 33 (25.5-40.6) |
| Without CCyR at baseline | 51/157 | 32 | 49/156 | 31 |
| Excluding Ph− patients | 49/155 | 32 | 52/159 | 33 |
| Imatinib-resistant | 34/117 | 29 | 38/116 | 33 |
| Imatinib-intolerant | 17/41 | 41 | 14/43 | 33 |
| PCyR | ||||
| Overall (95% CI) | 10/158 | 6 (3.1-11.3) | 16/159 | 10 (5.9-15.8) |
| Imatinib-resistant | 8/117 | 7 | 11/116 | 10 |
| Imatinib-intolerant | 2/41 | 5 | 5/43 | 12 |
| . | 140 mg once daily (n = 158) . | 70 mg twice daily (n = 159) . | ||
|---|---|---|---|---|
| n/N . | % . | n/N . | % . | |
| Hematologic response | ||||
| Overall (95% CI) | 119/158 | 75 (67.8-81.8) | 120/159 | 76 (68.0-81.9) |
| Imatinib-resistant | 83/117 | 71 | 86/116 | 74 |
| Imatinib-intolerant | 36/41 | 88 | 34/43 | 79 |
| MHR | ||||
| Overall (95% CI) | 105/158 | 66 (58.5-73.8) | 108/159 | 68 (60.1-75.1) |
| Without MHR at baseline | 78/129 | 60 | 73/118 | 62 |
| Imatinib-resistant | 74/117 | 63 | 79/116 | 68 |
| Imatinib-intolerant | 31/41 | 76 | 29/43 | 67 |
| CHR | ||||
| Overall (95% CI) | 75/158 | 47 (39.5-55.6) | 82/159 | 52 (43.5-59.6) |
| Without CHR at baseline | 63/142 | 44 | 59/128 | 46 |
| Imatinib-resistant | 59/117 | 50 | 59/116 | 51 |
| Imatinib-intolerant | 16/41 | 39 | 23/43 | 53 |
| NEL | ||||
| Overall (95% CI) | 30/158 | 19 (13.2-26.0) | 26/159 | 16 (11.0-23.0) |
| Imatinib-resistant | 15/117 | 13 | 20/116 | 17 |
| Imatinib-intolerant | 15/41 | 37 | 6/43 | 14 |
| MCyR | ||||
| Overall (95% CI) | 61/158 | 39 (31.0-46.7) | 68/159 | 43 (35.0-50.8) |
| Without MCyR at baseline | 48/143 | 34 | 57/147 | 39 |
| Excluding Ph− patients | 59/155 | 38 | 68/159 | 43 |
| Imatinib-resistant | 42/117 | 36 | 49/116 | 42 |
| Imatinib-intolerant | 19/41 | 46 | 19/43 | 44 |
| CCyR | ||||
| Overall (95% CI) | 51/158 | 32 (25.1-40.2) | 52/159 | 33 (25.5-40.6) |
| Without CCyR at baseline | 51/157 | 32 | 49/156 | 31 |
| Excluding Ph− patients | 49/155 | 32 | 52/159 | 33 |
| Imatinib-resistant | 34/117 | 29 | 38/116 | 33 |
| Imatinib-intolerant | 17/41 | 41 | 14/43 | 33 |
| PCyR | ||||
| Overall (95% CI) | 10/158 | 6 (3.1-11.3) | 16/159 | 10 (5.9-15.8) |
| Imatinib-resistant | 8/117 | 7 | 11/116 | 10 |
| Imatinib-intolerant | 2/41 | 5 | 5/43 | 12 |